Since IL-6 has been reported to stimulate the activation of JAK2/STAT3 signaling and such aberrant activation was generally associated with poor clinical prognosis, we assumed that upregulation of LRG1 in cancer cells might be attributed to activation of JAK2/STAT3 axis induced by CAFs-secreted IL-6. This evidence concerns the gene JAK2 and cancer.